Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact Post author:Sam Post published:October 29, 2017 Post category:BioPharma The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace You Might Also Like CARsgen Therapeutics Joins The Alliance For Regenerative Medicine June 29, 2017 15 In-Demand Life Science Jobs in Northern California June 21, 2017 Allecra Therapeutics New Antibiotic Shows Promise for Resistant Bacterial Infections March 25, 2018